Latest

Mankind Pharma and Innovent Biologics partner to revolutionise cancer care in India with innovative immunotherapy sintilimab

Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) and Innovent Biologics have announced a groundbreaking partnership to exclusively license and commercialise sintilimab, an advanced PD-1 immunotherapy, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region. Cancer...
-